Skin, our largest organ, acts as a protective barrier against pathogens that try to invade our bodies while constantly ...

University of York researchers have identified a protein called ESB2 that functions as a “molecular shredder” inside the ...

So, the current treatment options for chronic spontaneous urticaria include antihistamines, which have always been used at ...

The often fatal Ebola virus (EBOV) may linger in the body longer than previously understood. A recent report has raised ...

A rare form of leukemia known as TCF3::HLF-positive B cell acute lymphoblastic leukemia (B-ALL) sits among the most ...

Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat ...

New research suggests the skin does much more than detect damage or keep pathogens out. By tracing how skin cells respond to ...

Scientists have developed a novel protein evolution approach dubbed optovolution that uses light to guide the evolution of proteins with dynamic, multi-state, and computational functions based on ...

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been ...

Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead ...

Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 March 25, 2026 8:30 AM EDT Anupam Rama - JPMorgan Chase & Co, Research Division Konstantinos Biliouris - Oppenheimer & ...

Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that the first patient ...